New York reports death from EEE after 1st case diagnosed in nearly a decade

(NEW YORK) — Sara Anne Willette has spent more than 1,620 days in isolation since the start of the COVID-19 pandemic.

The New Jersey resident took health precautions in public before the pandemic because of her common variable immunodeficiency, which means she doesn’t make enough antibodies to fight infections.

Simple tasks like going for a walk down the street or taking a trip to the grocery store are laden with safety hurdles and anxiety for Willette.

Stressful tasks, like moving from Iowa to New Jersey during the pandemic for her husband’s new job, are now even more taxing. The two drove overnight to avoid crowds at gas stations and rest stops, and she’s prepared to do it again. The substantial health precautions in her day-to-day life are forcing her and her family to pack up their life once more and look for a new home in the countryside.

“I’m angry that society is largely inaccessible and I have to risk my life for the bare minimum, like medical care,” Willette told ABC News in a phone call. “Why live in civilization if all of it is completely inaccessible?”

More than four years after the start of the COVID-19 pandemic, Willette is among the immunocompromised and disabled Americans who’ve complete changed their way of living to survive.

Her anger was tinged with disappointment as she talked about how the rest of the world has gone back to normal despite the hundreds of people across the country dying from COVID-19 each week amid a summer surge of the virus.

COVID-19 has also been a debilitating event for tens of millions of people who have or are currently experiencing long COVID, which in some cases has been defined as a disability under the Americans with Disabilities Act.

With some lawmakers beginning to propose mask bans in hopes of reducing crime, it’s no longer an option for some to live life normally among the rest of society.

Willette was among the people ABC News checked back in with after previously talking to them about isolating two years after the pandemic began.

Finding a new normal

There are simple joys that Willette misses: having a garden, running, walking, letting her dogs run without a leash and drinking coffee on a porch.

She’s planning on moving to the mountains — somewhere between New Hampshire and Virginia — and gaining enough acreage to allow her and her family to embrace the activities they lost during the pandemic. However, being alone out in the countryside isn’t the goal for Willette.

Rather, she intends to build a pathogen-aware community. That means buying enough land so other disabled, immunocompromised or health-conscious able-bodied people who don’t want to get COVID-19 can join them and create a home of their own.

“We want something that feels like normal but is set up in a way that we decrease harm for everyone in the community,” Willette said. “We can’t do that in an urban area or even in a suburban area. There are too many risks.”

Her mother and mother-in-law intend to move and join Willette, her husband and her son on the property as well.

For Charis Hill, a California resident who has a systemic inflammatory disease and takes immunosuppressive medications, it’s been hard to access an in-person doctor’s appointment since many safety precautions for COVID-19 are no longer being taken in medical care facilities.

As someone with “high-level medical needs,” the lack of COVID precautions has even made seeking routine care a challenge.

“Just the fact that a medical environment that is supposed to know what a virus can do, most medical environments no longer require masking, and that’s what makes it unsafe for people like me to go, for anybody to go,” Hill told ABC over the phone.

“The impact of the delayed care, where people can’t go get routine care, that’s going to affect the whole health care system. Emergencies happen because of delayed care.”

Despite the stress and forced isolation, they find moments of joy growing their own food in their garden, and stay busy by working to reduce the local feral cat population through Trap-Neuter-Return practices.

They break their isolation monthly to meet at a park with a close-knit circle of friends who take similar safety precautions — they’re all masked, socially distanced and have tested beforehand.

“That’s really the only way for me to meet strangers and also to make new friends,” Hill said.

Mask bans would further bar immunocompromised people from public life, according to Hill.

Such bans “make it unsafe for us to exist,” Hill noted, because people may feel pressure not to wear masks when they’re sick or if immunocompromised people are worried about backlash for doing so.

With more people testing positive for COVID this summer, and with the fall and winter virus season ahead, Hill says society’s “new normal” should involve free testing, vaccines, access to at-home antiviral therapy paxlovid and flexible hybrid working options to mitigate the spread of illnesses.

“We need a new normal, and a new normal that is equitable for everyone, and that not only prioritizes high risk people, but that also reduces infection overall,” Hill said.

COVID concerns for the immunocompromised population

Immunocompromised people — about 3% of the adult population in the U.S., according to the National Institutes of Health — continue to face potentially serious medical complications or death when it comes to COVID-19. Even for those who were not previously at risk now have seen life-changing heath impacts.

“Long COVID can happen to anyone, and I have certainly seen young, healthy, vigorous athletes have prolonged, debilitating symptoms from long COVID,” Dr. Jeannina Smith, the medical director of University of Wisconsin’s Transplant Infectious Disease Program, told ABC over the phone.

However, society has largely appeared to have moved on. The CDC stopped recording some COVID-19 related data and some politicians have proposed mask bans as a potential solution to crime.

“It takes us a step back for public health,” Hill said. “We have other pandemics that are coming, and it’s going to make it harder to reenact mask mandates if we need them in the future.”

For the immunocompromised, regular society could seem like a minefield, according to Dr. Cassandra M. Pierre, the medical director of Public Health Programs and the associate hospital epidemiologist at Boston Medical Center.

She noted that people at higher risk for complications “are still, unfortunately, in our hospitals today. We see that they have this forced risk of going on to develop critical COVID or potentially even die. This is still occurring. COVID is still happening.”

This is all happening despite a better understanding of disease transmission and the information needed to be better equipped to empower communities to protect their health, Pierre added.

Patients have been harassed or mocked for wearing masks in public, Dr. Jeannina Smith noted, despite international and national medical organizations emphasizing the importance of mask wearing as a mitigation tactic for illnesses. Hill has experienced this first hand.

“You can’t look at someone and know that they’re receiving immunosuppression for an organ transplant or an autoimmune condition, and they remain at risk,” Smith said.

“Even if you don’t have individual risk, any person can still spread COVID to someone who has higher risk,” she said. “In fact, much of the spread continues to be from asymptomatic person. The very idea that we would criminalize wanting to protect our fellow citizens is pretty horrific.”

The federal government has recently changed its tune amid the summer COVID spike and is preparing for the upcoming fall and winter season by approving and granting emergency use authorization for updated COVID-19 vaccines and restarting its free at-home COVID tests program.

Copyright © 2024, ABC Audio. All rights reserved.

(WASHINGTON) When Congress passed the Inflation Reduction Act in 2022, there was a key provision that the Biden administration fought hard for. For years, private insurance companies negotiated with drug makers over prescription prices.

However, Medicare, representing 50 million seniors, did not have the same right to negotiate prices for its Part D coverage. This meant that Medicare basically had to accept the prices offered to them.

Health and Human Services Secretary Xavier Becerra joined “Start Here,” ABC News’ flagship daily news podcast, earlier this year to announce that negotiations were starting. They had selected 10 medications to prioritize and attempt to bargain down prices.

On Thursday, during the first public event held by President Biden and Vice President Harris since the Biden dropped out of the presidential race, they revealed that they had agreed on all issues. This is being described as a significant development for anyone on Medicare, and for anyone who pays taxes to fund the expenses of Medicare.

Secretary Becerra joined “Start Here” on Friday to discuss this further.

START HERE: Mr. Secretary, last time we spoke you had just identified the drugs…they included some diabetes drugs, some arthritis medications, treatments for blood clots and blood cancer. Where are we now?

BECERRA: We are done with the negotiation, Brad. We have completed 10 drugs. Every company joined in the negotiations. We had offers, counter offers, and we hit a sweet spot with all ten. And that sweet spot will save Americans on Medicare who need these drugs lots of money. And it will save taxpayers who help fund the Medicare program lots of money, in the billions.

START HERE: Yeah. How much of a discount are we talking about here?

BECERRA: So in some cases, the discount from the list price is up to 79%. I think the lowest discount is about 38%. And I do want to caveat that a bit. Very rarely does anybody pay list price for anything. And if you do, take it back and bargain a bit. Whether it’s that car at the dealership where you look at list price, you don’t pay that. When you go to the department store, you try to find everything you can on sale or, you know at some point it’s going to go on sale.

And so everybody makes the effort to try to get the best price for whatever the product is. In this case, it’s a very important product, it’s your prescription medication. But you should still be able to get a good price, and that’s what we did. We negotiated and got a much better price than what Medicare was getting.

START HERE: But just so we can we can be clear about that caveat. You’re saying it’s 68%, say it’s like 79% less than the list price. But you guys weren’t paying the list price earlier. Can you tell us how much you were paying on these drugs beforehand, and how much the new discount you’ve gotten is?

BECERRA:  Yeah. And that’s where it gets a little dicey because there are lots of nooks and crannies in the health care system. Some of them include what are, what is considered proprietary information of the companies, the drug companies, that they don’t want disclosed. And so the net price that Medicare pays is lower than the list price, but still high.

START HERE: So there’s some contract somewhere being like “You guys, no one can disclose what you guys had originally been paying.”

BECERRA: Yeah. We can’t, we can’t take you behind the curtain unless the drug companies tell us it’s okay to do so.

START HERE: Were you able to actually push back against these drug companies, or was it kind of like “We’ll ask once and then we’ll have to take what we get. We’re not going to risk not giving Americans these, these drugs.”

BECERRA:  Well, let’s just say that when they came in with their offer or counteroffer, the final price was neither our initial offer nor their official offer. But here’s what I will tell you. The Congressional Budget Office, which is Congress’ budget estimator, they’re the ones that keep tabs of what legislation will cost — will it save money or will it cost taxpayers money? And they are very stingy when it comes to saying “Oh, taxpayers will save money.” Right?

Well, the Congressional Budget Office said with regard to the Inflation Reduction Act and prescription drug negotiation, they said, we believe in the first year of negotiation — which we just finished — in that first year, and they’re projecting because they didn’t know which drugs it would be, etc.. They said, we believe the Department of Health Human Services will save $3.7 billion. Well, we’ve saved $6 billion.

And on top of that, we’re saving people out of pocket another billion and a half. But here’s the kicker. They said over 10 years, they assume that this new law, over 10 years of negotiating, will save $100 billion. So if we’re already almost double their first estimate for their first year, I guarantee you we’re going to do better than the 100 billion, over 10 years.

START HERE: Okay. When do the new prices go into effect, then I guess?

BECERRA: Jan. 1, 2026.

START HERE: Okay, so when that kicks in, how much of a discount will average Medicare patients actually see? Because, like, if you guys scored a 68% discount on Farxiga, like the diabetes kidney medication, does that mean that the person using that drug is going to pay, it doesn’t mean they’re going to pay 68% less. I mean, how much less would it be?

BECERRA: Yeah. So remember, and that’s also a difficult question because seniors don’t typically pay very much for their prescription medication. Medicare the program, that’s the beauty of Medicare, it covers the lion’s share of the cost of those drugs. Some Americans still have to pay some out-of-pocket costs for their drugs, especially the higher cost drugs. So we’re going to save folks quite a bit of money.

Let’s put it this way: I can talk to you in total aggregate terms. We can now look at the price that we negotiated and say “Okay, if we had this price back in 2023, what would our cost have been?” And the result is we would have saved $6 billion to the health care program, and Americans will be able to save about a billion and a half dollars collectively in their out-of-pocket costs.

START HERE: The trade group that represents companies like Pfizer, Lilly, Merck, they’ve said we might not see as much innovation because we’re not getting as much money. That’s, that’s constantly been sort of a critique of this. They also say that your math makes assumptions about how many people truly save money on this. They say a very small amount of people actually get this Part D plan in the way that would actually save the money here. What is your response to to to these pharmaceutical groups?

BECERRA:  Well, remember, they’re more than 50 million Americans who have prescription coverage under Medicare, the Part D program. There are about 9 million people in the Medicare program who use one of these 10 drugs. It’s not a small universe of people. And these are very expensive drugs. When you can bring the price down of a drug that’s listed for, say, $10,000, $12,000 to $3,000. That’s a pretty good deal. It’s still $3,000, but it sure saved you a ton of money. If you were paid $12,000 or 13,000 before that.

And so this will save not just the Medicare program money, but it will save Medicare beneficiaries money. And it certainly will pay taxpayers who today, when they work, have some of their money from their paycheck taken out so they could cover their Medicare investment into the future so that when they get turned 65, they can qualify. They will get to benefit from a strengthened Medicare program that will have those new resources available, because we didn’t have to spend it at, for overcharging us for the prescription medication.

START HERE: Well, so now, I mean, the idea is that you’ll negotiate more drug prices, right? So you got these 10 out of the way. What are the next 10 or the next 20, or do you guys have a sense of what types of drugs you’re looking to target?

BECERRA:  Yeah. And here I have to be careful, because everything we say about a drug can move the price on the market. Right? And I don’t want to be accused of trying to influence the price up or down. And so what I can tell you is the statute, the new law, the Inflation Reduction Act, gave a pretty clear prescription of how to select these, set of drugs that will be negotiated. That’s a, it’s a good thing in the way, in a sense that it doesn’t let politics enter into this. It was pretty clear which drugs count. In this case, the first 10, they had to be the most expensive drugs in the Medicare system.

START HERE: All right. So then we’ll see what happens next. All right. Secretary Xavier Becerra, thank you so much.

BECERRA: Brad, good to be with you.

Copyright © 2024, ABC Audio. All rights reserved.

(NEW YORK) — Health officials are warning Americans about a rare insect-borne virus that has infected several travelers.

As of Aug. 16, there have been 21 cases of Oropouche virus disease, sometimes called “sloth fever,” detected among U.S. travelers returning from Cuba, according to the Centers for Disease Control and Prevention (CDC).

The CDC said it wants clinicians and public health offices to be aware of the virus and to test for suspected cases, and for travelers to protect themselves from insect bites.

Here’s what you need to know about the virus:

What is ‘sloth fever’?

Oropouche virus is an arthropod-borne virus, meaning a type of virus spread to people by the bite of infected arthropods, a group of insects.

The virus is mainly spread to humans by infected culicoides prariensis, a species of biting midges, although it can be transmitted by certain mosquito species, according to the CDC.

It is sometimes called “sloth fever” because scientists investigating the virus first found it in a three-toed sloth and the virus naturally live in sloths, non-human primates and birds.

“I think that really stems from the role of sloths as hosts in that natural transmission cycle,” Dr. Chantal Vogels, an assistant professor of epidemiology at Yale School of Public Health, told ABC News. “But there’s other animals involved as well.”

Oropouche virus is endemic to the Amazon basin — including Bolivia, Colombia and Peru — and was first discovered in a human in 1955 in a febrile forest worker in a village in Trinidad and Tobago.

“The concern is that now it is spreading to Cuba and possibly elsewhere in the Caribbean, with imported cases in the U.S.,” Dr. Peter Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, told ABC News. “There is a possibility that it could gain a foothold in the southern U.S. especially in Gulf Coast states.”

What are the symptoms?

The incubation period of Oropouche virus disease is three to 10 days and matches symptoms of similar diseases including dengue, Zika and chikungunya.

Common symptoms include fever, headache, chills, muscle aches and joint pain, typically lasting about two to seven days and then disappearing.

Patients may experience other symptoms including nausea, vomiting, rash, sensitivity to light, dizziness and pain behind the eyes.

“This virus is an interesting one in that about a week later, 50% or more of people will have a recurrence of the symptoms,” Dr. Michael Angarone, an infectious diseases specialist at Northwestern Medicine in Chicago, told ABC News. “So, the symptoms will recur and, again, be present for around five days to seven days and then go away. So, I think that’s a very interesting aspect of this virus.”

How is it treated?

To be diagnosed with Oropouche virus disease, a health care provider will have to order laboratory tests.

There are no vaccines to prevent or medicines to treat Oropouche virus disease. Treatment mainly involves treating the symptoms including getting rest, preventing dehydration, and taking over-the-counter pain medicine, such as acetaminophen, according to the CDC.

The CDC advises against taking aspirin or other non-steroidal anti-inflammatory drugs until dengue can be ruled out to lower the risk of bleeding.

How do I prevent the virus?

The best prevention method is to prevent bites from midges or mosquitoes. The CDC recommends using insect repellent, having tight-fitting screens on windows and doors, wearing long-sleeve shirts and pants and using a fan when outdoors.

Currently there is no evidence of local transmission in the U.S; the only cases have been travel-related.

“Here in the U.S., I think travelers should be alert,” Vogels said. “If they travel to areas where there is ongoing transmission, they should be aware of potential symptoms upon return.”

There have also been recent reports of possible vertical transmission, which is when a pregnant person passes the infection to their baby in utero. The infection may result in adverse pregnancy outcomes, including fetal deaths and congenital malformations.

“This has been demonstrated in South America, but also in, I think, a few of the cases that are being looked at now from Cuba,” Angarone said. “There have been descriptions of fetal demise, so [miscarriage] or premature labor and congenital abnormalities, they have not been confirmed to be caused by the virus or the infection, and that’s what’s being looked into.”

The experts recommend that travelers — especially those who are older or immunocompromised — exercise further precautions when traveling to prevent infection.

Those who are pregnant and are considering travel to countries with an Oropouche virus Level 2 Travel Health Notice, reconsider nonessential travel, the CDC says.

Copyright © 2024, ABC Audio. All rights reserved.